Avadel Pharmaceuticals Completes Patient Enrollment in REVITALYZ Trial
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 18 2025
0mins
Avadel Pharmaceuticals announced the completion of patient enrollment in REVITALYZ, a Phase 3 trial evaluating LUMRYZTM extended-release oral suspension as a potential treatment for idiopathic hypersomnia. The primary objective of REVITALYZ is to demonstrate reduction in daytime sleepiness as measured by the primary endpoint, change in total score on the Epworth Sleepiness Scale at Week 14. Secondary endpoints will evaluate the effect of LUMRYZ on additional efficacy parameters including patient and clinician impression of change, idiopathic hypersomnia severity, and a measure of the functional outcomes of sleep.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AVDL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AVDL
Wall Street analysts forecast AVDL stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for AVDL is 20.29 USD with a low forecast of 18.50 USD and a high forecast of 22.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
0 Buy
10 Hold
0 Sell
Hold
Current: 21.560
Low
18.50
Averages
20.29
High
22.50
Current: 21.560
Low
18.50
Averages
20.29
High
22.50
About AVDL
Avadel Pharmaceuticals PLC is a biopharmaceutical company. The Company's product, LUMRYZ, is an extended-release formulation of sodium oxybate, indicated to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. Its approach includes applying solutions to the development of medications that address the challenges patients face with treatment options. Its drug delivery technologies include MICROPUMP, LIQUITIME, and MEDUSA. Its MICROPUMP technology allows for the development of modified-release solid, oral dosage formulations of drugs. Its LIQUITIME technology allows for the development of modified-release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its MEDUSA technology allows for the development of modified-release injectable dosage formulations of drugs.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
State Street Increases Stake in Avadel Pharmaceuticals by 2.39%
- Stake Increase: State Street Global Advisors and affiliates increased their stake in Avadel Pharmaceuticals plc on January 16, 2026, holding 2,326,632 shares, which represents 2.39% of total shares, indicating confidence and investment intent in the company.
- Transaction Details: In this transaction, State Street purchased a total of 29,196 shares at a price of $21.48 each, reflecting optimism about Avadel's future growth potential, which may influence the overall market perception of the stock.
- Market Reaction: This stake increase could attract market attention towards Avadel Pharmaceuticals, especially if the stock price remains stable, prompting investors to reassess the company's value and prospects.
- Disclosure Compliance: In accordance with the Irish Takeover Panel regulations, State Street's trading information was disclosed on January 19, 2026, ensuring transparency and compliance, which further enhances market trust in its regulatory adherence.
Continue Reading
State Street Increases Stake in Avadel Pharmaceuticals by 2.36%
- Stake Increase: State Street Global Advisors and its affiliates increased their stake in Avadel Pharmaceuticals plc on January 15, 2026, holding 2,298,069 shares, which represents 2.36% of total shares, indicating confidence and a long-term investment strategy in the company.
- Transaction Price: The purchase price per share was $621.48, reflecting market recognition of Avadel, which may influence its stock price trajectory and increase investor interest in the company.
- Market Impact: State Street's stake increase could enhance Avadel's visibility among investors, attracting more institutional interest and potentially driving up its stock price, thereby boosting market confidence.
- Future Outlook: With State Street's increased stake, Avadel Pharmaceuticals may gain more market support and resources in the future, further driving its business development and market expansion.
Continue Reading